Friday, April, 19, 2019 04:39:44

Category: Health

Santhera announces its intent to file application for CMA for Puldysa®

The authorized regulators have acknowledged the choice of pathway for conditional marketing authorization. Santhera Pharmaceuticals has announced its intention of filing an application with European Medicines Agency (EMA) for Conditional Marketing Authorization (CMA) for Puldysa® (idebenone) to treat respiratory dysfunction in Duchenne muscular dystrophy (DMD). …

Zynerba wins U.S. patent for CBD based Fragile X Syndrome treatment

The new patent will be valid until 2038 while the firm expects to present ongoing study reports by the second half of 2019. Zynerba Pharmaceuticals, Inc., the leading developer of innovative pharmaceutically-produced transdermal cannabinoid treatments designed for treating rare and near-rare neuropsychiatric disorders, has recently …

Glenmark and Grandpharma ink pact to commercialize Ryaltris in China

The terms of the agreement state that Glenmark will be accountable for developing and supplying Ryaltris across China. Globally renowned pharmaceutical major Glenmark Pharmaceuticals has reportedly announced that its Swiss subsidiary has signed an exclusive licensing pact with Grandpharma (China) Co. Credible sources claim that …